Senseonics (NYSE:SENS) experienced a rise in share prices after hours, following third-quarter results that exceeded sales expectations.
In post-market trading, SENS shares increased by 2.1%, reaching $6.87 each.
The Germantown, Maryland-based company, which specializes in long-term implantable continuous glucose monitoring (CGM) systems, reported a loss of $19.5 million, translating to 43¢ per share on revenues of $8.1 million for the quarter ending September 30, 2025.
Senseonics noted an 18.5% improvement in its bottom line, driven by a remarkable 90% increase in sales. Although the earnings per share fell short of Wall Street expectations by 3¢, the sales figures surpassed forecasts, which estimated revenues at $7.9 million.
The company attributed its growth to a significant 160% rise in new patients in the U.S. compared to the previous year.
This surge in new patients is a result of enhanced investments in direct-to-consumer (DTC) marketing, according to the company. September marked a record number of new patient starts in its history. This growth comes ahead of Senseonics taking full commercial responsibility for its Eversense 365 long-term implantable CGM systems next year, following the termination of its distribution agreement with Ascensia Diabetes Care.
(Discover more about Senseonics and the CGM market in our comprehensive MedTech Market Report on CGMs, available for purchase at MassDevice)
Senseonics anticipates total net revenue of around $35 million for the full year as it continues to roll out Eversense 365 in the U.S. This forecast assumes the company will approximately double its global patient base during 2025, aligning with the range previously projected by the company in August.
The company has also implemented a 1-for-20 reverse stock split, reducing the number of outstanding shares to about 41 million. Furthermore, it plans to move its stock exchange listing from the NYSE to the Nasdaq Global Market, effective November 17.
Insights from Senseonics Leadership and Analysts
Tim Goodnow, President and CEO of Senseonics, stated that the company is making strides in advancing its product portfolio. They expect to receive the CE mark for Eversense 365 by year-end, with a European launch slated for the first half of 2026. Goodnow also mentioned ongoing efforts toward an FDA investigational device exemption (IDE) submission for their next-generation Gemini transmitter-less CGM by the end of this year.
“The third quarter of 2025 was a record-setting period, marked by unprecedented levels of new patient shipments, insertions, and overall patient base,” Goodnow remarked. “Our hybrid DTC and provider commercial strategy continues to enhance awareness, competitiveness, and growth for Eversense 365, with approximately 90% of our new users transitioning from other CGMs. We believe that resuming commercialization of Eversense will empower us to steer our own course and maintain the momentum behind Eversense, driving further revenue growth.”
Analysts from BTIG, including Marie Thibault, Sam Eiber, and Alexandra Pang, have maintained a “Neutral” rating on Senseonics. They noted that management anticipates a likely one-time inventory adjustment as the company transitions its commercial operations. Ascensia typically maintains an inventory supply of around 60-90 days, while Senseonics aims for closer to 30 days, though they do not expect this to affect 2025 inventory levels.
The analysts also highlighted that the fourth quarter marks the one-year anniversary of the Eversense 365 launch, indicating that patients will be due for their first re-insertions.
“While we are encouraged by the progress [Senseonics] has made in promoting the adoption of Eversense 365, we remain cautious as we await more consistent commercial execution alongside operational leverage,” the analysts concluded.
